REGENNOVA, INC.
Orally-available small molecule inhibitor of polyamine synthesis for ADPKD treatment
- Sector
- Biotech
- Total capital
- $1.3M
- Federal grants
- $1.3M
- 3 awards · 2022–2025
- Rank in peer group#123 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Arginine-Polyamine Pathway Inhibitor for Treatment of ADPKD$349K
- Federal grantHealth and Human S · Phase I · A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia$500K
- Federal grantHealth and Human S · Phase I · Therapeutic Reduction of Cerebral Amyloid Angiopathy Pathologies in ADRD$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#123 · top 38%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 3- PendingAntimicrobial Peptide Compounds And Methods Of UseUSPTOApplication 18992791
- PendingAntimicrobial Peptide Compounds And Methods Of UseUSPTOApplication PCTUS2023070144
- PendingAntimicrobial Peptide Compounds And Methods Of UseUSPTOApplication 63368505
Related companies, and why
- EDITAS MEDICINE, INC.Similar federal contract value in Biotech · null in contracts
- ChromaDex Corp.Similar federal contract value in Biotech · null in contracts
- Amphista TherapeuticsSimilar federal contract value in Biotech · null in contracts
- DTx Pharma, Inc.Similar federal contract value in Biotech · null in contracts
- FORE US Bio Inc.Similar federal contract value in Biotech · null in contracts
- Inflammasome Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .